A healthcare provider may use Mitosol during glaucoma surgery. This medication works by preventing new cell growth at the site of the surgery, which may cause the surgery to fail. Your healthcare provider will administer product during surgery. Although most people do not experience any problems with it, side effects are possible and may include infection, inflammation, and cataracts.
What Is Mitosol?
Mitosol® (mitomycin ophthalmic) is a prescription medication approved for use during glaucoma surgery. It belongs to a general group of medicines known as antineoplastic antibiotics.
The active ingredient in Mitosol, mitomycin, is sometimes referred to as mitomycin-C. Mitomycin is also available in an intravenous (IV) injectable form. Injectable mitomycin is approved to treat stomach or pancreatic cancer.
Mitosol is made by Intas Pharmaceuticals, Ltd., for Mobius Therapeutics, LLC.
Mitosol works by preventing DNA from replicating. DNA replication is necessary for cells to multiply and grow. Oftentimes, the body will try to heal the hole created in the eye during glaucoma surgery, causing the hole to close up and the surgery to fail. By preventing DNA replication, Mitosol prevents new cell growth at the surgical site, thus prolonging the time it takes for the hole to close up.
Some general considerations to keep in mind when using this medicine include the following:
- Mitosol comes in the form of a powder that is dissolved in sterile water to form a liquid. It is applied directly to the eye during surgery.
- This medicine is normally applied by a healthcare provider in a healthcare setting.
- For Mitosol to work properly, it must be used as prescribed.